Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the benefic...
Автори: | Mcshane, H, Pathan, A, Sander, C, Goonetilleke, N, Fletcher, H, Hill, A |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
2005
|
Схожі ресурси
-
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
за авторством: Whelan, K, та інші
Опубліковано: (2009) -
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
за авторством: Fletcher, H, та інші
Опубліковано: (2008) -
Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
за авторством: Kathryn T. Whelan, та інші
Опубліковано: (2011-01-01) -
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
за авторством: Pathan, A, та інші
Опубліковано: (2012) -
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
за авторством: Pathan, A, та інші
Опубліковано: (2012)